Neurogene Inc’s recent filing unveils that its President and CFO Cvijic Christine Mikail unloaded Company’s shares for reported $76247.0 on Mar 13 ’25. In the deal valued at $16.94 per share,4,501 shares were sold. As a result of this transaction, Cvijic Christine Mikail now holds 72,343 shares worth roughly $0.57 million.
Then, Samsara BioCapital GP, LLC bought 48,770 shares, generating $1,259,623 in total proceeds. Upon buying the shares at $25.83, the 10% Owner now owns 1,717,127 shares.
Before that, Cvijic Christine Mikail bought 24,000 shares. Neurogene Inc shares valued at $491,400 were divested by the President and CFO at a price of $20.48 per share. As a result of the transaction, Cvijic Christine Mikail now holds 76,844 shares, worth roughly $0.6 million.
BMO Capital Markets initiated its Neurogene Inc [NGNE] rating to an Outperform in a research note published on June 27, 2024; the price target was $65. A number of analysts have revised their coverage, including Robert W. Baird’s analysts, who began to cover the stock in mid June with a ‘”an Outperform”‘ rating. Leerink Partners began covering NGNE with “an Outperform” recommendation on April 29, 2024. William Blair started covering the stock on March 21, 2024. It rated NGNE as “an Outperform”.
Price Performance Review of NGNE
On Monday, Neurogene Inc [NASDAQ:NGNE] saw its stock fall -10.52% to $7.86. Over the last five days, the stock has lost -32.84%. Neurogene Inc shares have fallen nearly -65.59% since the year began. Nevertheless, the stocks have fallen -81.55% over the past one year. While a 52-week high of $74.49 was reached on 02/06/25, a 52-week low of $8.50 was recorded on 04/07/25. SMA at 50 days reached $16.08, while 200 days put it at $30.90.
Levels Of Support And Resistance For NGNE Stock
The 24-hour chart illustrates a support level at 7.42, which if violated will result in even more drops to 6.98. On the upside, there is a resistance level at 8.55. A further resistance level may holdings at 9.24. The Relative Strength Index (RSI) on the 14-day chart is 24.13, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -3.88, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 97.88%. Stochastics %K at 3.72% indicates the stock is a buying.
How much short interest is there in Neurogene Inc?
A steep rise in short interest was recorded in Neurogene Inc stocks on 2025-03-14, growing by 0.43 million shares to a total of 2.18 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 1.75 million shares. There was a rise of 19.67%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on January 08, 2024 when H.C. Wainwright began covering the stock and recommended ‘”a Buy”‘ rating along with a $45 price target.
